Neural tumors such as glioblastoma (GBM) remain amongst tlie most difficult to treat. We have been interested in using oncolytic viruses, based on herpes simplex virus type 1 (HSV-1), as a selective nervous system tumor-killing virus. Considerable effort in the vector development resulted in the engineering of oncolytic HSV vectors (oHSV) such rQNestin34.5 that are non-toxic for normal cells, yet capable of selective replication in GBM tumor cells. In order to effectively use oHSV in animal tumor models it is necessary to propagate and purify oHSV to high titers. Efforts in process development have resulted in scalable systems capable of manufacturing rQNestin34.5 and other oHSVs. My laboratory has spent considerable time developing refined and novel methodologies to improve virus production, purification and quality assessment to provide high quality vector stocks with dramatically reduced levels of protein and DNA contaminants (>99% removal) that can contribute to toxicity, immunity and biodistribution as well as confound in vivo efficacy studies. Our efforts in process development have resulted in scalable systems capable of manufacturing these vectors for pre-clinical efficacy and safety testing resulting in a 10 to 30-fold increase in overall virus yield and a corresponding 60-fold increase in concentration of the virus. The Core is in the unique position of being one of a few sites for oHSV virus vector production, purification and quality assessment testing. This extensive expertise along with our prior collaborative interaction with the projects (33 oHSV vector stocks produced and distributed since October 2007) supports the overall success ofthe current proposal. The primary goal of the oHSV Production Core is to provide large quantities of GLP-grade concentrated and purified oHSV vectors: (i) rQNestin34.5 for Aims 1 &3 of Project 2, Aim 1-3 of Project 3, and Aims 1-3 of Project 4;(ii) transductional retargeted/miR-regulated oHSV vectors engineered in Aims 1-3 of Project 1, or (iii) ChaseABC armed versions of rQNestin34.5 for Aims 1-3 of Project 3 or the ChaseABC-armed retargeted vector engineered in for Aim 2-3 of Project 3. The oHSV Production Core m work with the projects to provide optimal vector quantity and purity while providing the support necessary to,successfully exploit the available technology. We will continue to refine our production, purification and assessment systems. Should any of the engineered oHSV vectors tested in the projects prove efficacious, the Core would provide support to cGMP facilities for transfer of the production/purification technology of large-scale oHSV manufacture for possible Phase-1 human clinical trials.

Public Health Relevance

The ACS predicts there will be >12,000 deaths/yr from brain cancer. Oncolytic Herpes Simplex Virus (oHSV) therapy has shown some promise. The goal ofthe POl is to improve on this process. Doing so requires hightiter purified stocks, consistently grown and purified by one lab otherwise considerable variation in purity, stability, sterility and identity occurs. Core B will provide the projects with highly purified oHSV stocks based on the detailed protocols we have developed for oHSV production, purification and quality assessment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Mazzacurati, Lucia; Marzulli, Marco; Reinhart, Bonnie et al. (2015) Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther 23:99-107
Nakashima, Hiroshi; Nguyen, Tran; Goins, William F et al. (2015) Interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1/p62. J Biol Chem 290:1485-95
Meisen, Walter Hans; Dubin, Samuel; Sizemore, Steven T et al. (2015) Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther 14:307-14
Bolyard, Chelsea; Yoo, Ji Young; Wang, Pin-Yi et al. (2014) Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clin Cancer Res 20:6479-94
Nakano, Ichiro (2014) Proneural-mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma? Future Oncol 10:1527-30
Bronisz, Agnieszka; Wang, Yan; Nowicki, Michal O et al. (2014) Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res 74:738-50
Nakashima, Hiroshi; Chiocca, E Antonio (2014) Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol 88:345-53
Kaufmann, Johanna K; Chiocca, E Antonio (2014) Glioma virus therapies between bench and bedside. Neuro Oncol 16:334-51
Wojton, Jeffrey; Meisen, Walter Hans; Jacob, Naduparambil K et al. (2014) SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget 5:9703-9
Ganguly, Ranjit; Hong, Christopher S; Smith, Luke G F et al. (2014) Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther 13:1393-8

Showing the most recent 10 out of 33 publications